enVVeno Medical/$NVNO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About enVVeno Medical
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.
Ticker
$NVNO
Sector
Primary listing
Employees
37
Headquarters
Website
enVVeno Medical Metrics
BasicAdvanced
$19M
-
-$1.20
1.01
-
Price and volume
Market cap
$19M
Beta
1.01
52-week high
$5.62
52-week low
$0.90
Average daily volume
867K
Financial strength
Current ratio
11.809
Quick ratio
11.656
Long term debt to equity
1.528
Total debt to equity
2.668
Profitability
EBITDA (TTM)
-23.789
Management effectiveness
Return on assets (TTM)
-38.59%
Return on equity (TTM)
-64.55%
Valuation
Price to book
0.56
Price to tangible book (TTM)
0.56
Price to free cash flow (TTM)
-1.092
Free cash flow yield (TTM)
-91.57%
Free cash flow per share (TTM)
-0.888
Growth
Earnings per share change (TTM)
-22.60%
3-year earnings per share growth (CAGR)
-21.89%
What the Analysts think about enVVeno Medical
Analyst ratings (Buy, Hold, Sell) for enVVeno Medical stock.
enVVeno Medical Financial Performance
Revenues and expenses
enVVeno Medical Earnings Performance
Company profitability
enVVeno Medical News
AllArticlesVideos
enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)
Accesswire·2 days ago
enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Accesswire·1 week ago
Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for enVVeno Medical stock?
enVVeno Medical (NVNO) has a market cap of $19M as of August 22, 2025.
What is the P/E ratio for enVVeno Medical stock?
The price to earnings (P/E) ratio for enVVeno Medical (NVNO) stock is 0 as of August 22, 2025.
Does enVVeno Medical stock pay dividends?
No, enVVeno Medical (NVNO) stock does not pay dividends to its shareholders as of August 22, 2025.
When is the next enVVeno Medical dividend payment date?
enVVeno Medical (NVNO) stock does not pay dividends to its shareholders.
What is the beta indicator for enVVeno Medical?
enVVeno Medical (NVNO) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.